Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 5 de 5
Filter
Add more filters










Database
Language
Publication year range
1.
Acta Anaesthesiol Scand ; 51(9): 1147-54, 2007 Oct.
Article in English | MEDLINE | ID: mdl-17711562

ABSTRACT

BACKGROUND: Paracetamol is often given as an adjunctive analgesic to reduce opioid-related adverse effects but its optimal dose is unknown. We studied the analgesic effect and safety of a single 3-g intravenous (i.v.) dose of paracetamol in adults. METHODS: One hundred and seven patients undergoing tonsillectomy under local anaesthesia were randomly allocated to receive i.v. 3 g of paracetamol, 75 mg of diclofenac or placebo prior to surgery. The consumption of post-operative morphine using a patient-controlled analgesia-device was quantified for 6 h. Platelet aggregation and the concentrations of paracetamol, liver aminotransferases, glutathione transferase alpha 1-1 (GSTA1-1) and thromboxane B(2) were measured. RESULTS: During the first hours after surgery, both paracetamol and diclofenac reduced (P < 0.05) the consumption of morphine but had no effect thereafter. The values for the 6-h cumulative consumption of morphine in patients given paracetamol (18.7 +/- 13.8 mg), diclofenac (16.1 +/- 9.9 mg) and placebo (22.0 +/- 12.1 mg) did not differ. Paracetamol had no effect on platelet aggregation, which was impaired only by diclofenac in response to arachidonic acid (P < 0.005). Both paracetamol (P < 0.01) and diclofenac (P < 0.005) inhibited the release of thromboxane B(2) at 1 h but they did not affect serum aminotransferase and GSTA1-1 levels. One patient given paracetamol displayed a transient increase in GSTA1-1 and liver aminotransferases. CONCLUSION: During the initial hours after tonsillectomy, the administration of 3 g of i.v. paracetamol and 75 mg of diclofenac reduced the consumption of morphine. Both drugs also reduced the release of thromboxane B(2) from activated platelets but only diclofenac had a negative effect on platelet aggregation. In sensitive individuals, large doses of paracetamol may disturb the hepatocellular integrity. We do not recommend the use of i.v. doses of paracetamol higher than 1 g.


Subject(s)
Acetaminophen/administration & dosage , Analgesics, Non-Narcotic/administration & dosage , Pain, Postoperative/prevention & control , Tonsillectomy , Acetaminophen/pharmacology , Adult , Analgesics, Non-Narcotic/pharmacology , Anesthesia, Local , Anti-Inflammatory Agents, Non-Steroidal/administration & dosage , Diclofenac/administration & dosage , Dose-Response Relationship, Drug , Double-Blind Method , Female , Glutathione Transferase/blood , Humans , Liver/enzymology , Male , Pain Measurement/drug effects , Platelet Aggregation/drug effects , Prospective Studies , Statistics, Nonparametric , Thromboxane B2/blood , Time Factors
2.
Br J Anaesth ; 97(2): 226-31, 2006 Aug.
Article in English | MEDLINE | ID: mdl-16698862

ABSTRACT

BACKGROUND: Acetaminophen (paracetamol) alone or in combination with other analgesics is widely used for postoperative analgesia. While acetaminophen and non-steroidal anti-inflammatory drugs inhibit platelet function, the cyclooxygenase-2 (COX-2) selectively inhibiting coxibs show no interference with platelet function. The authors studied the effect of a combination of i.v. parecoxib and acetaminophen on platelet function in healthy volunteers. METHODS: Eighteen healthy, male volunteers (22-33 yr) received i.v. acetaminophen 1 g, parecoxib 40 mg+acetaminophen 1 g or placebo in a double-blind, crossover study. Platelet function was assessed by photometric aggregometry and by measuring the release of thromboxane B(2). Plasma acetaminophen concentrations were measured by high-performance liquid chromatography. RESULTS: Platelet aggregation (median area under the curve) triggered with arachidonic acid 500 microM was 24.6, 3.9 and 4.2x10(3) area units (P=0.02, all groups) after placebo, acetaminophen and parecoxib+acetaminophen, respectively. Inhibition of platelet aggregation showed no difference between acetaminophen alone and the combination (P=0.82). Aggregation triggered with arachidonic acid 750 or 1000 microM, adenosine diphosphate (ADP) 1.5 or 3 microM, or epinephrine 5 microM showed no differences between the groups. Release of thromboxane B(2) in response to ADP was inhibited similarly by both acetaminophen and the combination. Plasma acetaminophen concentrations were similar after acetaminophen and the combination. CONCLUSIONS: Acetaminophen and parecoxib showed no interaction in inhibiting platelet function. In combination they cause a mild degree of COX-1 inhibition corresponding to that of acetaminophen alone.


Subject(s)
Acetaminophen/administration & dosage , Analgesics, Non-Narcotic/administration & dosage , Isoxazoles/administration & dosage , Platelet Aggregation/drug effects , Acetaminophen/blood , Adenosine Diphosphate/pharmacology , Adult , Analgesics, Non-Narcotic/blood , Arachidonic Acid/analysis , Arachidonic Acid/pharmacology , Blood Platelets/physiology , Cross-Over Studies , Cyclooxygenase Inhibitors/administration & dosage , Double-Blind Method , Drug Administration Schedule , Drug Interactions , Epinephrine/pharmacology , Humans , Infusions, Intravenous , Male , Thromboxane B2/blood
3.
Acta Anaesthesiol Scand ; 49(6): 840-6, 2005 Jul.
Article in English | MEDLINE | ID: mdl-15954969

ABSTRACT

BACKGROUND: Paracetamol (acetaminophen) is an effective analgesic and a weak inhibitor of cyclo-oxygenase (COX). Clinically paracetamol is often used together with traditional NSAIDs, which are strong inhibitors of COX. We studied binding of paracetamol to COX and its action on platelet function together with diclofenac. METHODS: Blood was collected from healthy donors and platelet function was assessed by photometric aggregometry, a platelet function analyser (PFA-100, Dade Behring, Deerfield, IL) and by measuring the release of thromboxane B(2) (TxB(2)), the stable metabolite of thromboxane A(2), after addition of paracetamol (10-80 microg ml(-1)). A concentration-inhibition relationship was established and the inhibition coefficient (K(i)) demonstrating 50% binding to COX was determined using a Schild-plot. Interaction of paracetamol (5-20 microg ml(-1)) and diclofenac (0.1-0.8 microg ml(-1)) was determined and an isobolographic analysis was performed. RESULTS: Paracetamol added to platelet-rich plasma (PRP) caused a concentration-dependent inhibition of platelet function. Photometric aggregometry and TxB(2) release was significantly inhibited by paracetamol from 10 microg ml(-1) onwards. The PFA-100 closure time was significantly prolonged by paracetamol at a high concentration only. K(i) was 15.2 microg ml(-1) with a 95% confidence interval of 11.8-18.6 microg ml(-1). Inhibition of aggregation by diclofenac was augmented by paracetamol. Isobolographic analysis showed synergism. CONCLUSIONS: The 95% confidence interval of K(i) equals the antipyretic plasma concentration of paracetamol, i.e. 10-20 microg ml(-1). High doses of paracetamol and a combination of diclofenac and paracetamol cause platelet inhibition and thus may increase risk of surgical bleeding.


Subject(s)
Acetaminophen/pharmacology , Analgesics, Non-Narcotic/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Diclofenac/pharmacology , Platelet Aggregation Inhibitors/pharmacology , Adult , Arachidonic Acid/antagonists & inhibitors , Arachidonic Acid/pharmacology , Cyclooxygenase Inhibitors/pharmacology , Dose-Response Relationship, Drug , Drug Interactions , Female , Humans , In Vitro Techniques , Male , Middle Aged , Platelet Activation/drug effects , Platelet Aggregation/drug effects , Platelet Function Tests , Prostaglandin-Endoperoxide Synthases/blood , Thromboxane B2/antagonists & inhibitors , Thromboxane B2/blood
4.
Br J Anaesth ; 91(3): 357-62, 2003 Sep.
Article in English | MEDLINE | ID: mdl-12925474

ABSTRACT

BACKGROUND: Acetaminophen (paracetamol) enhances the analgesic effect of non-steroidal anti-inflammatory drugs (NSAIDs). Acetaminophen is a weak inhibitor of cyclooxygenase (COX), and its combination with an NSAID may augment COX inhibition-related side effects. METHODS: Ten healthy male volunteers (21-30 yr) were given diclofenac 1.1 mg kg(-1) alone, a combination of propacetamol 30 mg kg(-1) (which is hydrolysed to 50% acetaminophen) and diclofenac 1.1 mg kg(-1) or placebo intravenously in a double blind, crossover study. Platelet function was assessed at 5 min, 90 min and 22-24 h by photometric aggregometry, platelet function analyser (PFA-100(TM)) and by measuring the release of thromboxane B(2) (TxB(2)). Analgesia was assessed with the cold pressor test. RESULTS: Platelet aggregation induced with arachidonic acid was fully inhibited by both diclofenac alone and the combination at the end of the 30-min drug infusion. Propacetamol augmented the inhibition by diclofenac at 90 min (P=0.014). At 22-24 h, platelet function had fully recovered. TxB(2) release was inhibited by the combination of propacetamol and diclofenac at 90 min in comparison with diclofenac alone (P=0.027). PFA-100(TM) detected no difference in platelet function between these two groups. No analgesic effect was detected with the cold pressor test. CONCLUSIONS: The combination of propacetamol and diclofenac inhibits platelet function more than diclofenac alone. This should be considered when assessing the risk of surgical bleeding.


Subject(s)
Acetaminophen/analogs & derivatives , Acetaminophen/pharmacology , Anti-Inflammatory Agents, Non-Steroidal/pharmacology , Blood Platelets/drug effects , Cyclooxygenase Inhibitors/pharmacology , Diclofenac/pharmacology , Platelet Aggregation/drug effects , Adult , Cross-Over Studies , Cyclooxygenase 1 , Double-Blind Method , Drug Synergism , Humans , Isoenzymes/antagonists & inhibitors , Male , Membrane Proteins , Pain Measurement , Platelet Function Tests/methods , Prostaglandin-Endoperoxide Synthases
5.
Biochem Mol Biol Int ; 35(2): 329-36, 1995 Feb.
Article in English | MEDLINE | ID: mdl-7663388

ABSTRACT

In this study we compare the uptake of spermine by mitochondria from Ehrlich ascites tumour cells with those from rat liver. The spermine uptake was membrane potential-dependent in both systems, but there were significant quantitative differences. The amount of spermine taken up by tumour mitochondria as a function of time was twice as large and a Lineweaver-Burk analysis showed that the Vmax was more than 6 times higher in tumour mitochondria. As in liver mitochondria, the uptake of spermine by ascites mitochondria was competitively inhibited by the polyamine spermidine and by putrescine. Mg2 was also inhibitory, as were the monovalent cations K+, Na+, Li+ and choline.


Subject(s)
Carcinoma, Ehrlich Tumor/metabolism , Carrier Proteins/metabolism , Mitochondria, Liver/metabolism , Mitochondria/metabolism , Spermine/metabolism , Animals , Biological Transport/drug effects , Cations, Monovalent/pharmacology , Kinetics , Magnesium/pharmacology , Male , Mice , Mice, Inbred ICR , Mitochondria/drug effects , Mitochondria, Liver/drug effects , Putrescine/pharmacology , Rats , Rats, Wistar , Spermidine/pharmacology
SELECTION OF CITATIONS
SEARCH DETAIL
...